Clinical Trial Update: Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing adjuvant versus progression-triggered gemcitabine monotherapy for locally advanced bladder cancer; trial status is currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Transitional Cell Carcinoma of the Bladder

Drugs mentioned

• Gemzar (gemcitabine)

Snippet

Sponsor: Association of Urologic Oncology (AUO) | Conditions: Bladder Cancer, Carcinoma, Transitional Cell | Phase 3 | Status: UNKNOWN